(Circulation. 1996;94:2146-2153.)
© 1996 American Heart Association, Inc.
Articles |
Predominance of Dense Low-Density Lipoprotein Particles Predicts Angiographic Benefit of Therapy in the Stanford Coronary Risk Intervention Project
the Life Sciences Division (B.D.M., R.M.K.), E.O. Lawrence Berkeley National Laboratory, University of California (Berkeley); and Stanford University School of Medicine (E.L.A., W.L.H., J.M.F.), Palo Alto, Calif.
Background LDL particles differ in size and density. Individuals with LDL profiles that peak in relatively small, dense particles have been reported to be at increased risk of coronary artery disease. We hypothesized that response to coronary disease therapy in such individuals might differ from response in individuals whose profiles peak in larger, more buoyant LDL. We examined this hypothesis in the Stanford Coronary Risk Intervention Project, an angiographic trial that compared multifactorial risk-reduction intervention with the usual care of physicians.
Methods and Results For 213 men, a bimodal frequency distribution of peak LDL density (g/mL) determined by analytical ultracentrifugation was used to classify baseline LDL profiles as "buoyant mode" (density 
1.0378) or "dense mode" (density >1.0378). Coronary disease progression after 4 years was assessed by rates of change (mm/y, negative when arteries narrow) of minimum artery diameter. Rates for buoyant-mode subjects were -0.038±0.007 (mean±SEM) in usual care (n=65) and -0.039±0.010 in intervention (n=56; P=.6). Rates for dense-mode subjects were -0.054±0.012 in usual care (n=51) and -0.008±0.009 in intervention (n=41, P=.007). Lipid changes did not account for this difference in angiographic response.
Conclusions Different types of LDL profile may predict different responses to specific therapies, perhaps because metabolic processes determine both LDL profiles and responses to therapies.
Key Words: angiography • atherosclerosis • coronary disease • drugs • lipoproteins
This article has been cited by other articles:
 |
|
 |
|
  S. Shrestha, H. C. Freake, M. M. McGrane, J. S. Volek, and M. L. Fernandez A Combination of Psyllium and Plant Sterols Alters Lipoprotein Metabolism in Hypercholesterolemic Subjects by Modifying the Intravascular Processing of Lipoproteins and Increasing LDL Uptake J. Nutr., May 1, 2007; 137(5): 1165 - 1170. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Tsimikas, J. T. Willerson, and P. M. Ridker C-reactive protein and other emerging blood biomarkers to optimize risk stratification of vulnerable patients. J. Am. Coll. Cardiol., April 18, 2006; 47(8 Suppl): C19 - C31. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Rizzo and K. Berneis Low-density lipoprotein size and cardiovascular risk assessment QJM, January 1, 2006; 99(1): 1 - 14. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. M. Krauss Dietary and Genetic Probes of Atherogenic Dyslipidemia Arterioscler. Thromb. Vasc. Biol., November 1, 2005; 25(11): 2265 - 2272. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Bosse, L. Perusse, and M.-C. Vohl Genetics of LDL particle heterogeneity: from genetic epidemiology to DNA-based variations J. Lipid Res., June 1, 2004; 45(6): 1008 - 1026. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. M. Krauss Lipids and Lipoproteins in Patients With Type 2 Diabetes Diabetes Care, June 1, 2004; 27(6): 1496 - 1504. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. McKenney New Perspectives on the Use of Niacin in the Treatment of Lipid Disorders Arch Intern Med, April 12, 2004; 164(7): 697 - 705. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Frohlich and M. Dobiasova Fractional Esterification Rate of Cholesterol and Ratio of Triglycerides to HDL-Cholesterol Are Powerful Predictors of Positive Findings on Coronary Angiography Clin. Chem., November 1, 2003; 49(11): 1873 - 1880. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. M. Sacks and H. Campos Low-Density Lipoprotein Size and Cardiovascular Disease: A Reappraisal J. Clin. Endocrinol. Metab., October 1, 2003; 88(10): 4525 - 4532. [Full Text] [PDF]
|
|
|
|
 |
|
 References Circulation, December 17, 2002; 106(25): 3373 - 3421. [Full Text]
|
|
|
|
|
|
K. K. Berneis and R. M. Krauss Metabolic origins and clinical significance of LDL heterogeneity J. Lipid Res., September 1, 2002; 43(9): 1363 - 1379. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Miremadi, A. Sniderman, and J. Frohlich Can Measurement of Serum Apolipoprotein B Replace the Lipid Profile Monitoring of Patients with Lipoprotein Disorders? Clin. Chem., March 1, 2002; 48(3): 484 - 488. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. A. Kreisberg and A. Oberman Lipids and Atherosclerosis: Lessons Learned from Randomized Controlled Trials of Lipid Lowering and Other Relevant Studies J. Clin. Endocrinol. Metab., February 1, 2002; 87(2): 423 - 437. [Full Text] [PDF]
|
|
|
|
|
|
C. M. Ballantyne, A. G. Olsson, T. J. Cook, M. F. Mercuri, T. R. Pedersen, and J. Kjekshus Influence of Low High-Density Lipoprotein Cholesterol and Elevated Triglyceride on Coronary Heart Disease Events and Response to Simvastatin Therapy in 4S Circulation, December 18, 2001; 104(25): 3046 - 3051. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. D. Sniderman, T. Scantlebury, and K. Cianflone Hypertriglyceridemic HyperapoB: The Unappreciated Atherogenic Dyslipoproteinemia in Type 2 Diabetes Mellitus Ann Intern Med, September 18, 2001; 135(6): 447 - 459. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Zambon, S. S. Deeb, B. G. Brown, J. E. Hokanson, and J. D. Brunzell Common Hepatic Lipase Gene Promoter Variant Determines Clinical Response to Intensive Lipid-Lowering Treatment Circulation, February 13, 2001; 103(6): 792 - 798. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M. Hoefner, S. D. Hodel, J. F. O'Brien, E. L. Branum, D. Sun, I. Meissner, and J. P. McConnell Development of a Rapid, Quantitative Method for LDL Subfractionation with Use of the Quantimetrix Lipoprint LDL System Clin. Chem., February 1, 2001; 47(2): 266 - 274. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. D. Sniderman, J. Bergeron, and J. Frohlich Apolipoprotein B versus lipoprotein lipids: vital lessons from the AFCAPS/TexCAPS trial Can. Med. Assoc. J., January 1, 2001; 164(1): 44 - 47. [Full Text] [PDF]
|
|
|
|
|
|
S. M. Grundy Cholesterol-Lowering Therapy in Secondary Prevention: Remaining Issues J. Clin. Endocrinol. Metab., June 1, 2000; 85(6): 2092 - 2098. [Full Text]
|
|
|
|
|
|
A. Oberman Hypertriglyceridemia and Coronary Heart Disease J. Clin. Endocrinol. Metab., June 1, 2000; 85(6): 2098 - 2105. [Full Text]
|
|
|
|
|
|
T. A. Jacobson, G. G. Griffiths, C. Varas, D. Gause, J. C. Y. Sung, and C. M. Ballantyne Impact of Evidence-Based "Clinical Judgment" on the Number of American Adults Requiring Lipid-Lowering Therapy Based on Updated NHANES III Data Arch Intern Med, May 8, 2000; 160(9): 1361 - 1369. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. R. Superko and R. M. Krauss Garlic powder, effect on plasma lipids, postprandial lipemia, low-density lipoprotein particle size, high-density lipoprotein subclass distribution and lipoprotein(a) J. Am. Coll. Cardiol., February 1, 2000; 35(2): 321 - 326. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. C. Maki, M. H. Davidson, M. S. Cyrowski, A. C. Maki, and P. Marx Low-Density Lipoprotein Subclass Distribution Pattern and Adiposity-Associated Dyslipidemia in Postmenopausal Women J. Am. Coll. Nutr., February 1, 2000; 19(1): 23 - 30. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Lee, F. Sigari, T. Segrado, S. Horkko, S. Hama, P. V. Subbaiah, M. Miwa, M. Navab, J. L. Witztum, and P. D. Reaven All ApoB-Containing Lipoproteins Induce Monocyte Chemotaxis and Adhesion When Minimally Modified : Modulation of Lipoprotein Bioactivity by Platelet-Activating Factor Acetylhydrolase Arterioscler. Thromb. Vasc. Biol., June 1, 1999; 19(6): 1437 - 1446. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Zambon, J. E. Hokanson, B. G. Brown, and J. D. Brunzell Evidence for a New Pathophysiological Mechanism for Coronary Artery Disease Regression : Hepatic Lipase–Mediated Changes in LDL Density Circulation, April 20, 1999; 99(15): 1959 - 1964. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. M Dreon, H. A Fernstrom, P. T Williams, and R. M Krauss A very-low-fat diet is not associated with improved lipoprotein profiles in men with a predominance of large, low-density lipoproteins Am. J. Clinical Nutrition, March 1, 1999; 69(3): 411 - 418. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. M. Ballantyne, J. A. Herd, L. L. Ferlic, J. K. Dunn, J. A. Farmer, P. H. Jones, J. R. Schein, and A. M. Gotto Jr Influence of Low HDL on Progression of Coronary Artery Disease and Response to Fluvastatin Therapy Circulation, February 16, 1999; 99(6): 736 - 743. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. S. Rosenson and C. C. Tangney Antiatherothrombotic Properties of Statins: Implications for Cardiovascular Event Reduction JAMA, May 27, 1998; 279(20): 1643 - 1650. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. R. Superko Beyond LDL Cholesterol Reduction Circulation, November 15, 1996; 94(10): 2351 - 2354. [Full Text]
|
|